Del Laboratories, Inc., to License Elizabeth Arden Trademarks for Salon Nail Care Products

Del Laboratories, Inc., to License Elizabeth Arden Trademarks for Salon Nail
Care Products 


UNIONDALE, N.Y., March 25  /PRNewswire-FirstCall/ -- Del Laboratories, Inc. 
today announced a trademark licensing agreement for the use of the Elizabeth
Ardenand Red Door trademarks for salon nail care products.  The products will
be developed and marketed by Del Laboratories and sold under the Elizabeth Arden
and Red Door names.

William McMenemy, Executive Vice President of Marketing at Del said, "Our
expertise in the nail care business together with the great Elizabeth Arden and
Red Door salon and spa heritage provide a unique selling proposition based on
the strengths of both companies.  The new line will provide salons and nail
technicians with a complete line of the highest quality products, carrying the
well known and prestigious Elizabeth Arden and Red Door trademarks."

This agreement marks the first entree into the professional salon channel for
Del, the number one manufacturer of nail care products to the mass marketing
channel.  The first products will begin to roll out later this year and will be
marketed to the Elizabeth Arden and Red Door spas and prestige salons and spas
nationwide.

Del Laboratories, Inc., markets and manufactures cosmetics and over-the- counter
pharmaceuticals. Its major brands include SALLY HANSEN HARD AS NAILS(R),
America's number one nail protection, HEALING BEAUTY(R) skin care makeup,
CORNSILK(R) face makeup, LACROSS(R) nail and beauty implements, lip color, skin
care, bleaches and depilatories, all under the SALLY HANSEN brand franchise,
NATURISTICS(R) cosmetics, and N.Y.C. New York Color(R) cosmetics. The Company's
Del Pharmaceuticals subsidiary includes ORAJEL(R), the number one brand of
topical oral analgesics, ARTHRICARE(R), PRONTO(R), DERMAREST(R) PSORIASIS,
GENTLE NAUTRALS(R), AURO-DRI(R), TANAC(R) and PROPA pH(R).

Elizabeth Arden and Red Door are registered trademarks of Elizabeth Arden, Inc.

Certain statements in this press release may constitute"forward-looking
statements" under the federal securities laws.  Forward-looking statements
contain information that is subject to certain risks, uncertainties, trends and
other factors that could cause actual results to be materially different from
any future results implied by such forward-looking statements.  Factors that
might cause such a difference include, but are not limited to: delays in
introducing new products or failure of consumers to accept new products; actions
by competitors which mayresult in mergers, technology improvement or new
product introductions; the dependence on certain national chain drug stores,
food stores and mass merchandiser relationships due to the concentration of
sales generated by such chains; changes in fashion-oriented color cosmetic
trends; the effect on sales of lower retailer inventory targets; the effect on
sales of political and/or economic conditions; the Company's estimates of costs
and benefits, cash flow from operations and capital expenditures; interest rate
or foreign exchange rate changes affecting the Company and its market sensitive
financial instruments including the Company's qualitative and quantitative
estimates as to market risk sensitive instruments; changes in product mix to
products which are less profitable; shipment delays; depletion of inventory and
increased production costs resulting from disruptions of operations at any of
our manufacturing or distribution facilities; foreign currency fluctuations
affecting our results of operations and the value of our foreign assets and
liabilities; the relative prices at which we sell our products and our foreign
competitors sell their products in the same market; our operating and
manufacturing costs outside of the United States; changesin the laws,
regulations and policies, including changes in accounting standards, that
effect, or will effect, us in the United States and/or abroad; and trends in the
general economy.  Although the Company believes that the expectations reflected
in such forward-looking statements are based upon reasonable assumptions, it can
give no assurance that its expectations will be achieved.  Without limitation,
use of the following words is intended to identify forward-looking statements:
"may," "will," "should," "expect," "anticipate," "estimate," "intend," "plan,"
or "continue" or the negative thereof or other variations thereon.  For further
information on factors which could impact the Company and the statements
contained herein, please refer to the Company's filings with the Securities and
Exchange Commission, including without limitation the Company's Annual Report on
Form 10-K and the "Management's Discussion and Analysis of Financial Condition
and Results of Operations" contained or incorporatedby reference therein and
quarterly reports on Form 10-Q. Filings with the Securities and Exchange
Commission are available on the Company's website at http://www.dellabs.com/. 

DATASOURCE: Del Laboratories, Inc.



CONTACT:  William H. McMenemy, Executive Vice President of Del

Laboratories, Inc., [phone]



Web site:  http://www.dellabs.com/ 

Copyright